A Phase 2 interventional study of Anifrolumab in Lupus Erythematosus, Systemic, sponsored by MedImmune LLC. Completed at 57 sites in 13 countries. Open to participants aged 18 Years to 68 Years. Per ClinicalTrials.gov, last updated 2019-07-31.
Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing anifrolumab in Lupus Erythematosus, Systemic — 9 open to participants now, 11 under way, 6 of them phase 3. anifrolumab · Lupus Erythematosus, Systemic.
Among the 20 studies testing anifrolumab in Lupus Erythematosus, Systemic, this one is the 10th largest by enrollment, is the only one that started in 2013, is one of 6 in phase 2, and was the 3rd registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →9 of the 20 studies testing anifrolumab in Lupus Erythematosus, Systemic are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Australia, Belgium, Chile and 7 more countries
Ages 5–17
AstraZeneca · Sites in United States, Argentina, Australia and 32 more countries
Ages 5–80
AstraZeneca · Sites in China
Ages 18–70
AstraZeneca · Sites in United States, Canada, France and 6 more countries
Ages 18–70
AstraZeneca · Sites in United States
Ages 18–130 · Women only
By country, each count listing its studies:
anifrolumab: first FDA approval 2021 (SAPHNELO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years to 68 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2013.
This study's enrollment of 218 is above the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 159 across the 20 interventional studies. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 20 have an industry lead sponsor. The 5 most frequent:
This study is registered under MedImmune LLC, one of the names counted as AstraZeneca. Under that name alone:
MedImmune LLC is the lead sponsor of 270 studies on the registry; none are open to participants now.
Of its 52 completed or terminated interventional studies of FDA-regulated products, 29 (56%) have results posted.
46 studies in Lupus Erythematosus, Systemic by AstraZeneca: 19 open now, 25 under way, 6 of them phase 3. Of 20 finished, 11 (55%) have results posted.
Among the 46 studies in Lupus Erythematosus, Systemic by AstraZeneca, this one is the 11th largest by enrollment of the 26 interventional ones that give a count, is the only one that started in 2013, is one of 9 in phase 2, and was the 8th registered.
AstraZeneca’s Lupus Erythematosus, Systemic studies by the year they started, since 2008.
4 of the studies testing anifrolumab in Lupus Erythematosus, Systemic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05138133Phase 3AstraZenecaPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | 2027-02-23 |
| NCT05440422National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD | 2027-08-01 |
| NCT06594068AstraZenecaProspective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users | 2027-08-31 |
| NCT07913919University of CambridgeEffect of Anifrolumab on Arterial Inflammation in Systemic Lupus Erythematosus Study | 2027-09-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 20 studies testing anifrolumab in Lupus Erythematosus, Systemic, from their registry updates:
Among AstraZeneca’s 46 in Lupus Erythematosus, Systemic:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the long-term safety of anifrolumab (MEDI-546) in adults with moderate to severe active systemic lupus erythematosus (SLE).
This is an open-label extension study to evaluate long-term safety and tolerability of intravenous (IV) anifrolumab in adult participants with moderately-to-severely active SLE. Participants must have completed the qualifying Phase 2 study and meet this study criteria in order to be eligible.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive IV infusion of anifrolumab 1000 milligrams (mg) every 4 weeks (Q4W) from Day 1 (Week 0) until 12-Feb-2015 (approval of protocol amendment 4); and thereafter will receive 300 mg Q4W for up to 3 years or until the sponsor discontinued development of anifrolumab, whichever came first.
Biological: Anifrolumab
Intravenous infusion of anifrolumab will be administered as 1000 mg Q4W from Day 1 (Week 0) until 12-Feb-2015 (approval of protocol amendment 4); and thereafter 300 mg Q4W up to 3 years or until the sponsor discontinued development of anifrolumab, whichever came first.
Also known as: MEDI-546
Number of Particpants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event is any AE that resulted in death, life threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, is a congenital anomaly/birth defect in offspring of a study participant, is an important medical event that may jeopardize the participant or may require medical intervention. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.
Time frame: From first dose of study drug (Day 1) through 168 weeks
Number of Participants With Adverse Events Resulting in Discontinuation (DAEs) of Anifrolumab
Number of participants with DAEs are reported.
Time frame: From first dose of study drug (Day 1) through 168 weeks
Number of Participants With Adverse Events of Special Interest (AESIs)
An AESI is scientific and medical concern specific to understanding of the study drug. An AESI may be serious or non-serious. Number of participants with AESIs are reported.
Time frame: From first dose of study drug (Day 1) through 168 weeks
Number of Participants With Positive Anti-Drug Antibodies (ADA) Titer to Anifrolumab
The number of participants with positive serum antibodies to anifrolumab at anytime (including baseline) are reported.
Time frame: Baseline (Pre-dose on Day 1) up to Week 168
Anti-Drug Antibodies (ADA) Titer to Anifrolumab
Median ADA titer in participants with ADA-positive assessments and reportable ADA titer results are reported.
Time frame: Baseline (Pre-dose on Day 1) up to Week 168
Number of ADA-positive Participants With Decreased Serum Concentration of Anifrolumab
Number of participants with decreased serum concentration of anifrolumab due to ADA-positive results are reported.
Time frame: Baseline (Pre-dose on Day 1) up to Week 168
Number of ADA-positive Participants With Decreased Pharmacodynamics Response of Anifrolumab
Number of participants with decreased pharmacodynamic response of anifrolumab due to ADA-positive results are reported.
Time frame: Baseline (Pre-dose on Day 1) up to Week 168
Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) Global Score for ADA Positive Participants
The SLEDAI-2K is an activity index that measures disease activity and records feature of active lupus as present or not present. SLEDAI-2K uses a weighted checklist to assign a numerical score based on the presence or absence of 24 symptoms. Each symptom present is assigned between 1 and 8 points based on its usual clinical importance, yielding a total score that ranges from 0 points (no symptoms) to 105 points (presence of all defined symptoms).
Time frame: Baseline (Pre-dose on Day 1); and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 160, and 168
Number of ADA-positive Participants With TEAEs and TESAEs
The number of ADA-positive participants with TEAEs and TESAEs are reported.
Time frame: Baseline (Pre-dose on Day 1) up to Week 168
The study was conducted from 28 Mar 2013 to 18 Jul 2018.
| Milestone | Anifrolumab |
|---|---|
| Started | 218 |
| Completed | 172 |
| Not completed | 46 |
| Withdrew: Withdrawal by subject | 23 |
| Withdrew: Lost to follow-up | 6 |
| Withdrew: Death | 1 |
| Withdrew: Other | 16 |
An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event is any AE that resulted in death, life threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, is a congenital anomaly/birth defect in offspring of a study participant, is an important medical event that may jeopardize the participant or may require medical intervention. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.
| Participants | Anifrolumab |
|---|---|
| TEAEs | 170 |
| TESAEs | 50 |
Number of participants with DAEs are reported.
| Participants | Anifrolumab |
|---|---|
| Number of Participants With Adverse Events Resulting in Discontinuation (DAEs) of Anifrolumab | 17 |
The number of participants with positive serum antibodies to anifrolumab at anytime (including baseline) are reported.
| Participants | Anifrolumab |
|---|---|
| Number of Participants With Positive Anti-Drug Antibodies (ADA) Titer to Anifrolumab | 5 |
Median ADA titer in participants with ADA-positive assessments and reportable ADA titer results are reported.
| Antibody titers | Anifrolumab |
|---|---|
| Anti-Drug Antibodies (ADA) Titer to Anifrolumab | 120 (30 to 120) |
Number of participants with decreased serum concentration of anifrolumab due to ADA-positive results are reported.
| Participants | Anifrolumab |
|---|---|
| Number of ADA-positive Participants With Decreased Serum Concentration of Anifrolumab | 1 |
Number of participants with decreased pharmacodynamic response of anifrolumab due to ADA-positive results are reported.
| Participants | Anifrolumab |
|---|---|
| Number of ADA-positive Participants With Decreased Pharmacodynamics Response of Anifrolumab | 1 |
The SLEDAI-2K is an activity index that measures disease activity and records feature of active lupus as present or not present. SLEDAI-2K uses a weighted checklist to assign a numerical score based on the presence or absence of 24 symptoms. Each symptom present is assigned between 1 and 8 points based on its usual clinical importance, yielding a total score that ranges from 0 points (no symptoms) to 105 points (presence of all defined symptoms).
| Units on Score | Anifrolumab |
|---|---|
| Baseline | 7.8 ± 7.6 |
| Week 12 | 5 ± 2.0 |
| Week 24 | 1.5 ± 1.9 |
| Week 36 | 2.0 ± 2.3 |
| Week 48 | 1.8 ± 2.0 |
| Week 60 | 2.0 ± 1.6 |
| Week 72 | 4.0 ± 5.7 |
| Week 84 | 3.0 ± 1.4 |
| Week 96 | 3.0 ± 1.4 |
| Week 108 | 4.0 ± 0.0 |
| Week 120 | 5.0 ± 1.4 |
| Week 132 | 4.0 ± 0.0 |
| Week 144 | 7.0 ± 7.1 |
| Week 156 | 6.0 ± 2.8 |
| Week 160 | 2.0 ± 2.8 |
| Week 168 | 2.0 ± 2.8 |
The number of ADA-positive participants with TEAEs and TESAEs are reported.
| Participants | Anifrolumab |
|---|---|
| TEAEs | 5 |
| TESAEs | 1 |
An AESI is scientific and medical concern specific to understanding of the study drug. An AESI may be serious or non-serious. Number of participants with AESIs are reported.
| Participants | Anifrolumab |
|---|---|
| Herpes zoster | 11 |
| Drug hypersensitivity | 1 |
| Hypersensitivity | 2 |
| Infusion related reaction | 4 |
| Nausea | 1 |
| Hodgkin's disease | 1 |
| Latent tuberculosis | 5 |
| Hypersensitivity vasculitis | 1 |
| Vasculitis | 1 |
Collected over From first dose of study drug (Day 1) through 168 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Anifrolumab | 1/218 (0.5%) | 50/218 (22.9%) | 164/218 (75.2%) |
| Event | Anifrolumab |
|---|---|
| Systemic lupus erythematosusMusculoskeletal and connective tissue disorders | 5/218 |
| PneumoniaInfections and infestations | 4/218 |
| BronchitisInfections and infestations | 2/218 |
| Chikungunya virus infectionInfections and infestations | 2/218 |
| GastroenteritisInfections and infestations | 2/218 |
| Post procedural infectionInfections and infestations | 2/218 |
| Urinary tract infectionInfections and infestations | 2/218 |
| Femur fractureInjury, poisoning and procedural complications | 2/218 |
| OsteonecrosisMusculoskeletal and connective tissue disorders | 2/218 |
| Spinal column stenosisMusculoskeletal and connective tissue disorders | 2/218 |
| Event | Anifrolumab |
|---|---|
| NasopharyngitisInfections and infestations | 32/218 |
| BronchitisInfections and infestations | 28/218 |
| Upper respiratory tract infectionInfections and infestations | 20/218 |
| HeadacheNervous system disorders | 14/218 |
| Urinary tract infectionInfections and infestations | 13/218 |
| DiarrhoeaGastrointestinal disorders | 11/218 |
| Herpes zosterInfections and infestations | 10/218 |
| PharyngitisInfections and infestations | 10/218 |
| InfluenzaInfections and infestations | 9/218 |
| SinusitisInfections and infestations | 8/218 |
As-treated population included all participants who received any dose of study drug in the OLE study.
| Age, Continuous(Years) | Anifrolumab |
|---|---|
| Mean | 40.8 ± 12.2 |
| Sex: Female, Male(Participants) | Anifrolumab |
|---|---|
| Female | 203 |
| Male | 15 |
| Ethnicity (NIH/OMB)(Participants) | Anifrolumab |
|---|---|
| Hispanic or Latino | 104 |
| Not Hispanic or Latino | 114 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Anifrolumab |
|---|---|
| American Indian or Alaska Native | 4 |
| Asian | 11 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 29 |
| White | 87 |
| More than one race | 2 |
| Unknown or Not Reported | 85 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AstraZeneca's policy is to share data with researchers if the request is in scope of our policy. Additional information can be found on astrazenecaclinicaltrials.com.
Ran from Mar 2013 to primary completion in Jul 2018, 63 months.
Results were first posted in Jul 2019, 1 year after primary completion.
Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's 63 months is above that.
Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Anifrolumab
Lupus Erythematosus, Systemic →